ESC 365 - Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

ESC Premium Access

Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session type: Rapid Fire Abstracts

Date: 28 August 2018

Time: 16:45 - 17:45

Congress Session

6 presentations in this session

Type of P2Y12 inhibitor at the acute stage and one-year mortality in acute myocardial infarction. The FAST-MI programme

Speaker: Professor N. Danchin (Paris, FR)

A head-to-head comparison of uniform prasugrel treatment vs. clopidogrel treatment for confirmed responders in acute coronary syndrome patients: results from the randomized TROPICAL-ACS trial

Speaker: Doctor R. Hein (Munich, DE)

Prasugrel vs Ticagrelor in patients with acute coronary syndrome and diabetes: a propensity match substudy of RENAMI

Speaker: Doctor M. Bertaina (Turin, IT)

Next generation P2Y12 inhibitors improve survival in ACS: An analysis from the British Cardiovascular Intervention Society database.

Speaker: Doctor H. Contractor (Manchester, GB)

Prognostic impact of the new P2Y12 (ticagrelor and prasugrel) versus clopidogrel in acute coronary syndrome patients in relation to renal function

Speaker: Mrs M. Castineira Busto (Vigo, ES)

The OPTIDUAL trial: long term follow-up

Speaker: Professor G. Helft (Paris, FR)

6 speakers from this session

Professor Nicolas Danchin

AP-HP - European Hospital Georges Pompidou, Paris (France)

13 presentations

0 follower

Doctor Ralph Hein

Klinikum Neuperlach, Munich (Germany)

0 follower

Doctor Maurizio Bertaina

San Giovanni Battista – Molinette Hospital, Turin (Italy)

0 follower

Doctor Hussain Contractor

Manchester University Hospitals, Manchester (United Kingdom of Great Britain & Northern Ireland)

0 follower

Mrs Maria Castineira Busto

University Hospital Alvaro Cunqueiro, Vigo (Spain)

0 follower

Professor Gerard Helft

Institut de Cardiologie, Paris (France)

0 follower

This platform is supported by